



# CLAIMS


1. A therapeutic agent for schizophrenia, which comprises, as an active ingredient, a compound of the formula (I)




5 wherein  $\text{R}^1$  is a  $\text{C}_2$ - $\text{C}_6$  alkyl group or the formula (II)




wherein  $\text{R}^2$  is a hydrogen atom or an acetyl group and  $\text{R}^3$  is a  $\text{C}_1$ - $\text{C}_6$  alkyl group, a cycloalkyl group or



10 wherein  $\text{R}^4$  and  $\text{R}^5$  are each independently a hydrogen atom or a  $\text{C}_1$ - $\text{C}_6$  alkyl group, and in





of the formula (II),  $\text{R}^2$  and  $\text{R}^3$  may be linked to each other to form




15

wherein  $\text{R}^6$  is a hydrogen atom or a  $\text{C}_1$ - $\text{C}_6$  alkyl group;




wherein  $R^7$  and  $R^8$  are each independently a hydrogen atom or a  $C_1$ - $C_4$  alkyl group,




5

wherein  $R^9$  and  $R^{10}$  are each independently a hydrogen atom or a  $C_1$ - $C_4$  alkyl group,



10 wherein  $R^{11}$  is a hydrogen atom or a  $C_1$ - $C_4$  alkyl group; and




wherein  $R^{12}$  and  $R^{13}$  are each independently a  $C_1$ - $C_4$  alkyl group or may be linked to each other to form




15


wherein  $n$  is an integer of 2 to 6, or



wherein m is an integer of 2 or 3,



wherein  $R^{14}$  is a hydrogen atom or a  $C_1$ - $C_4$  alkyl group,




5


wherein  $R^{15}$  is a hydrogen atom or an aralkyl group, or



provided that when




10




and  $R^7$  should not be a hydrogen atom, an enantiomer thereof, an acid addition salt thereof, or a hydrate or solvate thereof.


2. The therapeutic agent of claim 1, wherein the compound of  
15 the formula (I) is a compound of the formula (Ia)




wherein  $\text{R}^{1'}$  is a  $\text{C}_2\text{-C}_6$  alkyl group or the formula (II)',




wherein  $\text{R}^2$  is a hydrogen atom or an acetyl group, and  $\text{R}^{3'}$  is a  
 5  $\text{C}_1\text{-C}_6$  alkyl group or





wherein  $\text{R}^4$  and  $\text{R}^5$  are each independently a hydrogen atom or a  
 $\text{C}_1\text{-C}_6$  alkyl group, and in



10 of the formula (II)',  $\text{R}^2$  and  $\text{R}^{3'}$  may be linked to each other to form




wherein  $\text{R}^6$  is a hydrogen atom or a  $\text{C}_1\text{-C}_6$  alkyl group;  
 $\text{R}^{9'}$  and  $\text{R}^{10'}$  are each independently a  $\text{C}_1\text{-C}_4$  alkyl group; and




wherein  $R^{15}$  is an aralkyl group, or




- 5 3. The therapeutic agent of claim 1, wherein the compound of the formula (I) is a 4-acylamino-5,6,7,8-tetrahydrofuro[2,3-b]quinoline derivative of the formula (Ib)



wherein  $R^{16}$  is a  $C_2-C_6$  alkyl group,



or



10

wherein  $R^6$  is a hydrogen atom or a  $C_1-C_6$  alkyl group; and  $R^9$  and  $R^{10}$  are each independently a hydrogen atom or a  $C_1-C_4$  alkyl group.

- 15 4. The therapeutic agent of claim 1, wherein the compound of the formula (I) is 2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetamide.

5. The therapeutic agent of any of claims 1-4, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.

5